The Hyperkalemia Treatment Market to Witness Substantial Growth in North America
Hyperkalemia is a diseases in which levels of potassium are higher than normal level in blood serum. An individual is prone to develop hyperkalemia when the consumption of potassium exceeds. Hyperkalemia can occur due to diabetic kidney disease, chronic kidney disease, or congestive heart failure. It is diagnosed by glucose monitoring, blood tests, creatinine blood test, and kidney functioning test. Other hyperkalemia treatment options include IV calcium, diuretics, albuterol, insulin, and sodium bicarbonate. While mild hyperkalemia is usually asymptomatic, high levels of potassium may cause life-threatening paralysis, muscle weakness, or cardiac arrhythmias. Rising prevalence of chronic kidney disease and cardiac arrhythmias are major factors driving the hyperkalemia treatment market growth. According to the Centers for Disease Control and Prevention (CDC), more than one in seven (around 37 million people in the U.S.) are estimated to have chronic kidney disease. Moreover...